SINTX Technologies Advances SiN/PEEK 3D Printing Platform Toward Personalized Orthopedic Implant Commercialization
Key Highlights
- ➤SINTX completed advanced 3D-printing facility buildout and received EXT-220 MED systems
- ➤SINTX expects proprietary SiN/PEEK filament from Evonik before year-end 2026
- ➤Initial custom extremity implant opportunities targeted for first-quarter 2027
- ➤FDA 510(k) clearance pursued for patient-specific extremity implant design envelope
- ➤SINTX plans CMF and spinal application expansion later in 2027, subject to regulatory review
Expert Statements
Eric K. Olson, Chairman and Chief Executive Officer of SINTX Technologies
“We believe our SiN/PEEK technology represents a potentially significant commercial growth opportunity for SINTX”
Eric K. Olson, Chairman and Chief Executive Officer of SINTX Technologies
“We are bringing together years of proprietary biomaterials research, differentiated intellectual property, advanced additive manufacturing, and personalized surgical technologies to establish an integrated commercial platform.”
Eric K. Olson, Chairman and Chief Executive Officer of SINTX Technologies
“Our objective is to deliver patient-specific solutions that combine the design flexibility of 3D printing with the unique biological and mechanical properties of silicon nitride.”
Company completes additive manufacturing facility buildout, advances proprietary silicon nitride–PEEK technology, expands leadership and targets initial product availability in 2027
SALT LAKE CITY, Utah, Nov. 11, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials technology company focused on silicon nitride-based solutions, today provided a strategic business update on the continued product development and planned commercialization of its proprietary silicon nitride–polyetheretherketone (SiN/PEEK) composite technology through its SiNERGY(™) additive manufacturing platform.
Get started
Create a free account to read the full story.